~~<i id='673F24CF71'><strike id='673F24CF71'><tt id='673F24CF71'><pre id='673F24CF71'></pre></tt></strike></i>~~

Home» focus» entertainment

entertainment

author：entertainment 2025-08-24 23:08:44 Page View：1

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Donor acceptance rates hint at racial, gender bias in heart transplants: study
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

explore

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

In Spain, a hospital brews its own CAR

MikeReddyforSTATBARCELONA,Spain—Someofthepatientswaitingintheoncologywardofahospitalhere,withitsgree

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Patient advocates debate FDA's accelerated approval process

Fromleft,STAT'sAllisonDeAngelis,ALSadvocateCathyCollet,Yale'sGreggGonsalves,SickCells'AshleyValentin